A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.
NCT00042679
Completed
The purposes of this study are to determine the following: Whether LY900003 plus gemcitabine and carboplatin can make your tumor smaller or disappear, and for how long. If treatment with LY900003 plus gemcitabine and carboplatin can help you live longer. The safety of LY900003 plus gemcitabine and carboplatin and any side effects that might be associated with the combination of these three drugs. How LY900003 is distributed and broken down by your body when it is given with carboplatin and g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2006
Locations: Not set, Bakersfield, California +10 locations
Conditions: Carcinoma, Non-Small-Cell Lung, Pulmonary Neoplasms, Neoplasms, Lung
Register for Updates
ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
NCT00051493
Completed
The purpose of this study is to evaluate the effects (good and bad) of LY231514 (ALIMTA) and Carboplatin on you and your non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2006
Locations: Not set, Houston, Texas
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.
NCT00051506
Completed
The purpose of this study is to evaluate the effects (good and bad) of ALIMTA plus Carboplatin or ALIMTA plus Cisplatin on you and your small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2006
Locations: For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Springdale, Arkansas +7 locations
Conditions: Lung Neoplasms
Register for Updates
Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer
NCT00150657
Unknown
* this study is being done to find out if the combination of carboplatin and gemcitabine will be more effective in the the treatment of advanced lung cancer if bevacizumab, an agent that blocks tumor blood vessel formation, is added * the study will measure the time to progression of patients treated with the combination; we hope to show that the addition of bevacizumab improves the time to progression (increases the amount of time before the disease begins to worsen) * all patients receive all... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/28/2005
Locations: Providence Cancer Institute, Southfield, Michigan
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Selective Dose Escalation for Esophageal Cancer
NCT00139633
Unknown
This prospective study was designed to assess the outcomes (survival and failure patterns) of therapy for localized esophageal cancer with conventional dose radiation (RT; 50.4 Gy) with concurrent continuous infusion 5-fluorouracil (5-FU) and weekly carboplatin/paclitaxel. Patients with less than complete response (CR) or partial response (PR) received dose escalation of radiation to 59.4 Gy with the same chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2005
Locations: The Oregon Clinic, Portland, Oregon
Conditions: Esophageal Cancer
Register for Updates